OSLO, Norway, September 27, 2011 /PRNewswire/ -- - Strategic collaboration with Ipsen for marketing rights in Europe and the rest of the world

OSLO, Norway, August 23, 2011 /PRNewswire/ -- Algeta ASA (OSE: ALGETA), a company focused on the development of novel targeted cancer therapeutics, today announced that

OSLO, Norway, June 6, 2011 /PRNewswire-FirstCall/ -- - Trial Stopped Based on Data Results from Pre-Planned Interim Analysis; Patients in Placebo Arm Will Be Offered Treatment with Radium-223 Chloride Algeta ASA (OSE: ALGETA) today announced that the Phase III ALSYMPCA (radium-223 chloride in SYMptomatic Prostate CAncer) trial evaluating the investigational compound radium-223 chloride, which is exclusively licensed by Bayer, in patients with castration-resistant prostate cancer (CRPC) and bone metastases met its primary endpoint by significantly improving overall survival.

RICHMOND, Calif., Oct.

LAS VEGAS, March 24 /PRNewswire/ -- ISC West 2010 -- Nio® Security, Inc.